Engineered immune cells take aim at Hard-to-Treat lymphoma
NCT ID NCT07453446
First seen Mar 08, 2026 · Last updated May 04, 2026 · Updated 5 times
Summary
This early-stage study is testing a new treatment called CD30-targeted CAR-T cells for people with a type of lymphoma that has returned or not responded to standard therapy. The treatment involves taking a patient's own immune cells, modifying them to recognize and attack cancer cells with the CD30 marker, and infusing them back. The main goals are to check the safety of the therapy and see if it can shrink tumors. About 18 adults aged 18 to 70 with CD30-positive lymphoma are being enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hebei Yanda Lu Daopei Hospital
RECRUITINGSanhe, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.